secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001503274-24-000014
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix restates prior financials for inventory errors; Q3 revenue $35.7M (+13% YoY)
--------------------------------------------------------------------------------

- Revenue $35.7M (+13% YoY); GAAP gross margin 58.9%; reaffirms FY2024 revenue guidance $134-138M.
- Restating financials for 2021-2024 due to inventory capitalization errors; non-reliance on prior statements.
- Estimated restatement impacts: 2023 gross profit +$2.1M, operating loss -$2.3M; no material impact on cash or revenue.
- Material weaknesses in internal control over inventory valuation continue; remediation ongoing.
- Launched LucentAD Complete multi-marker Alzheimer's test; Mt. Sinai deploying blood-based biomarkers using Quanterix assays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327424000014/0001503274-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327424000014/qtrx-20241111.htm
  HTML page:      https://secwatch.observer/filing/0001503274-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer